Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| B cell | 21 studies | 26% ± 10% | |
| naive B cell | 12 studies | 22% ± 6% | |
| memory B cell | 11 studies | 22% ± 4% | |
| precursor B cell | 5 studies | 43% ± 12% | |
| epithelial cell | 5 studies | 22% ± 5% | |
| immature B cell | 4 studies | 32% ± 10% | |
| astrocyte | 4 studies | 22% ± 4% | |
| endothelial cell | 3 studies | 21% ± 3% | |
| pro-B cell | 3 studies | 49% ± 7% | |
| germinal center B cell | 3 studies | 20% ± 3% | |
| GABAergic neuron | 3 studies | 28% ± 3% | |
| glutamatergic neuron | 3 studies | 31% ± 6% | |
| oligodendrocyte precursor cell | 3 studies | 21% ± 4% | |
| oligodendrocyte | 3 studies | 20% ± 3% | |
| abnormal cell | 3 studies | 23% ± 4% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 4 studies | 27% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 942.01 | 1445 / 1445 | 100% | 13.64 | 183 / 183 |
| lung | 100% | 807.64 | 578 / 578 | 100% | 17.98 | 1155 / 1155 |
| breast | 100% | 1054.43 | 459 / 459 | 100% | 18.37 | 1117 / 1118 |
| brain | 100% | 815.77 | 2639 / 2642 | 100% | 18.40 | 705 / 705 |
| intestine | 100% | 1312.14 | 966 / 966 | 100% | 18.66 | 526 / 527 |
| thymus | 100% | 1216.55 | 653 / 653 | 100% | 14.11 | 603 / 605 |
| stomach | 100% | 976.99 | 359 / 359 | 100% | 17.49 | 285 / 286 |
| bladder | 100% | 990.19 | 21 / 21 | 100% | 13.58 | 502 / 504 |
| ovary | 100% | 936.87 | 180 / 180 | 100% | 11.44 | 428 / 430 |
| uterus | 100% | 977.26 | 170 / 170 | 99% | 13.41 | 456 / 459 |
| kidney | 100% | 1130.75 | 89 / 89 | 99% | 11.98 | 894 / 901 |
| pancreas | 100% | 627.76 | 328 / 328 | 99% | 11.07 | 176 / 178 |
| liver | 100% | 729.44 | 226 / 226 | 99% | 8.61 | 401 / 406 |
| prostate | 100% | 925.82 | 245 / 245 | 99% | 10.32 | 495 / 502 |
| adrenal gland | 100% | 1068.86 | 258 / 258 | 97% | 9.83 | 224 / 230 |
| skin | 100% | 1052.71 | 1808 / 1809 | 97% | 11.36 | 457 / 472 |
| adipose | 100% | 953.73 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 20.94 | 29 / 29 |
| muscle | 100% | 2024.21 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1780.03 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 13.23 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 3.54 | 1 / 1 |
| blood vessel | 100% | 755.72 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 1134.60 | 848 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 88% | 7.63 | 70 / 80 |
| peripheral blood | 86% | 810.52 | 802 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0070681 | Biological process | glutaminyl-tRNAGln biosynthesis via transamidation |
| GO_0031647 | Biological process | regulation of protein stability |
| GO_0032543 | Biological process | mitochondrial translation |
| GO_0030956 | Cellular component | glutamyl-tRNA(Gln) amidotransferase complex |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0050567 | Molecular function | glutaminyl-tRNA synthase (glutamine-hydrolyzing) activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0005524 | Molecular function | ATP binding |
| Gene name | QRSL1 |
| Protein name | Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial (Glu-AdT subunit A) (EC 6.3.5.7) (Glutaminyl-tRNA synthase-like protein 1) Glutaminyl-tRNA amidotransferase subunit QRSL1 |
| Synonyms | |
| Description | FUNCTION: Allows the formation of correctly charged Gln-tRNA(Gln) through the transamidation of misacylated Glu-tRNA(Gln) in the mitochondria. The reaction takes place in the presence of glutamine and ATP through an activated gamma-phospho-Glu-tRNA(Gln). . FUNCTION: Allows the formation of correctly charged Gln-tRNA(Gln) through the transamidation of misacylated Glu-tRNA(Gln) in the mitochondria. The reaction takes place in the presence of glutamine and ATP through an activated gamma-phospho-Glu-tRNA(Gln). . |
| Accessions | B2RBJ8 Q9H0R6 X6R772 ENST00000369046.8 [Q9H0R6-1] ENST00000369044.1 |